Movement Alert｜AstraZeneca PLC Rises 4.97% in Regular Trading, Rebound After Bristol Myers Merger Rumor Officially Denied

Market Focus08-05 21:39

On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by merger speculation.

On the news front, multiple senior sources close to the matter explicitly confirmed that AstraZeneca and Bristol Myers Squibb have never engaged in any merger discussions. The denial effectively quashed earlier reports from August 3 suggesting the two companies were exploring a potential $400 billion combination that would have created one of the world's largest pharmaceutical companies. AstraZeneca had previously fallen over 9% on the unconfirmed merger speculation, with analysts from BMO Capital noting that neither company possessed sufficient financial capacity to fund such a transaction — AstraZeneca could raise approximately $37 billion, far below the $400 billion required.

Additionally, CSPC Pharmaceutical Group announced it signed a joint venture contract with AstraZeneca and received a $10 million milestone payment under a strategic R&D collaboration agreement, signaling positive business expansion momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166845622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166845622","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca PLC Rises 4.97% in Regular Trading, Rebound After Bristol Myers Merger Rumor Officially Denied","media":"Market Focus","content":"<p><p>On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by merger speculation.</p><p>On the news front, multiple senior sources close to the matter explicitly confirmed that AstraZeneca and Bristol Myers Squibb have never engaged in any merger discussions. The denial effectively quashed earlier reports from August 3 suggesting the two companies were exploring a potential $400 billion combination that would have created one of the world's largest pharmaceutical companies. AstraZeneca had previously fallen over 9% on the unconfirmed merger speculation, with analysts from BMO Capital noting that neither company possessed sufficient financial capacity to fund such a transaction — AstraZeneca could raise approximately $37 billion, far below the $400 billion required.</p><p>Additionally, CSPC Pharmaceutical Group announced it signed a joint venture contract with AstraZeneca and received a $10 million milestone payment under a strategic R&amp;D collaboration agreement, signaling positive business expansion momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca PLC Rises 4.97% in Regular Trading, Rebound After Bristol Myers Merger Rumor Officially Denied</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca PLC Rises 4.97% in Regular Trading, Rebound After Bristol Myers Merger Rumor Officially Denied\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by merger speculation.</p><p>On the news front, multiple senior sources close to the matter explicitly confirmed that AstraZeneca and Bristol Myers Squibb have never engaged in any merger discussions. The denial effectively quashed earlier reports from August 3 suggesting the two companies were exploring a potential $400 billion combination that would have created one of the world's largest pharmaceutical companies. AstraZeneca had previously fallen over 9% on the unconfirmed merger speculation, with analysts from BMO Capital noting that neither company possessed sufficient financial capacity to fund such a transaction — AstraZeneca could raise approximately $37 billion, far below the $400 billion required.</p><p>Additionally, CSPC Pharmaceutical Group announced it signed a joint venture contract with AstraZeneca and received a $10 million milestone payment under a strategic R&amp;D collaboration agreement, signaling positive business expansion momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1166845622","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166845622","pubTimestamp":1785937144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"走势警报|阿斯利康公司常规交易上涨 4.97%，百时美合并传闻正式否认后反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by merger speculation.On the news front, multiple senior sources close to the matter explicitly confirmed that AstraZeneca and Bristol Myers Squibb have never engaged in any merger discussions. The denial effectively quashed earlier reports from August 3 suggesting the two companies were exploring a potential $400 billion combination that would have created one of the world's largest pharmaceutical companies. AstraZeneca had previously fallen over 9% on the unconfirmed merger speculation, with analysts from BMO Capital noting that neither company possessed sufficient financial capacity to fund such a transaction — AstraZeneca could raise approximately $37 billion, far below the $400 billion required.Additionally, CSPC Pharmaceutical Group announced it signed a joint venture contract with AstraZeneca and received a $10 million milestone payment under a strategic R&D collaboration agreement, signaling positive business expansion momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166845622","isCrawlerRequest":true}